Payment overview · 2025
General Payments
$2,724.47
137 reported records · 28 companies
Healthcare provider profile · identity verified
Patrick Edward Gilhool, DO
Allopathic & Osteopathic Physicians|Family Medicine · ELIZABETHTOWN, PA · NPI 1902848948
Verified facts
What the public records show
CMS Open Payments records show Patrick Edward Gilhool, DO received $2,724.47 in general payments during 2025 across 137 reported records.
AstraZeneca Pharmaceuticals LP accounted for 11.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 798 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 798 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $301.80 | 11.1% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $293.39 | 10.8% | 25 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $205.78 | 7.5% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $200.50 | 7.4% | 9 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $199.77 | 7.3% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $186.54 | 6.8% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $171.85 | 6.3% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $166.80 | 6.1% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $122.18 | 4.5% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $121.75 | 4.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $107.26 | 3.9% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $85.08 | 3.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.68 | 2.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $60.22 | 2.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.85 | 2.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $46.90 | 1.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $43.71 | 1.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.35 | 1.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.33 | 1.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.17 | 1.4% | 2 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $31.52 | 1.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $28.88 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.31 | 0.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.90 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.86 | 0.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.15 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.64 | 0.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.30 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,681.97 | 136 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $245.67 | 8 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $199.77 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $192.34 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $186.54 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $182.53 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $178.39 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $156.44 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.45 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $141.23 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $141.23 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $133.25 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $130.08 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $128.65 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $123.43 | 13 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $123.43 | 13 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $123.41 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $122.18 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $121.75 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $98.78 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $84.47 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.68 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $60.22 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $60.22 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $54.85 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $46.90 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $43.71 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $31.52 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $29.88 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $29.88 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $29.88 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.40 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $28.88 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.25 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 798 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
798 | 78 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
798 | 78 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1579 | 198 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1108 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 1069 | 140 |
| Sertraline Hcl | Sertraline Hcl | 1039 | 80 |
| Omeprazole | Omeprazole | 937 | 146 |
| Furosemide | Furosemide | 871 | 120 |
| Eliquis | Apixaban | 798 | 78 |
| Metformin Hcl | Metformin Hcl | 788 | 126 |
| Lisinopril | Lisinopril | 779 | 114 |
| Gabapentin | Gabapentin | 774 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 758 | 104 |
| Potassium Chloride | Potassium Chloride | 586 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 552 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 549 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 539 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 443 | 55 |
| Simvastatin | Simvastatin | 437 | 55 |
| Mirtazapine | Mirtazapine | 422 | 46 |
| Losartan Potassium | Losartan Potassium | 411 | 63 |
| Divalproex Sodium | Divalproex Sodium | 348 | 17 |
| Warfarin Sodium | Warfarin Sodium | 328 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 319 | 24 |
| Carvedilol | Carvedilol | 317 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 316 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 77 |
| Risperidone | Risperidone | 303 | 19 |
| Trazodone Hcl | Trazodone Hcl | 294 | 33 |
| Buspirone Hcl | Buspirone Hcl | 291 | 31 |
| Lorazepam | Lorazepam | 289 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 285 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 265 | 46 |
| Tramadol Hcl | Tramadol Hcl | 265 | 59 |
| Famotidine | Famotidine | 252 | 40 |
| Donepezil Hcl | Donepezil Hcl | 240 | 39 |
| Lamotrigine | Lamotrigine | 216 | suppressed |
| Ezetimibe | Ezetimibe | 215 | 19 |
| Gemtesa | Vibegron | 212 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 44 |
| Olanzapine | Olanzapine | 195 | 15 |
| Torsemide | Torsemide | 194 | suppressed |
| Aripiprazole | Aripiprazole | 188 | 12 |
| Montelukast Sodium | Montelukast Sodium | 186 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 184 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 39 |
| Baclofen | Baclofen | 174 | 43 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 173 | suppressed |
| Levetiracetam | Levetiracetam | 170 | 13 |
| Finasteride | Finasteride | 165 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 21 |
| Meloxicam | Meloxicam | 152 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 151 | 26 |
| Spironolactone | Spironolactone | 146 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 142 | 27 |
| Primidone | Primidone | 141 | suppressed |
| Allopurinol | Allopurinol | 139 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 139 | suppressed |
| Celecoxib | Celecoxib | 137 | 12 |
| Memantine Hcl | Memantine Hcl | 137 | 19 |
| Propranolol Hcl | Propranolol Hcl | 133 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 132 | 22 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 128 | 27 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 121 | 19 |
| Xarelto | Rivaroxaban | 121 | 16 |
| Valsartan | Valsartan | 117 | 11 |
| Atenolol | Atenolol | 115 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 113 | 72 |
| Alprazolam | Alprazolam | 108 | 26 |
| Azithromycin | Azithromycin | 108 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 35 |
| Bupropion Hcl | Bupropion Hcl | 101 | suppressed |
| Januvia | Sitagliptin Phosphate | 99 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 45 |
| Bumetanide | Bumetanide | 91 | 16 |
| Ozempic | Semaglutide | 89 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 25 |
| Digoxin | Digoxin | 85 | suppressed |
| Gemfibrozil | Gemfibrozil | 84 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 79 | 12 |
| Clonazepam | Clonazepam | 78 | 12 |
| Pregabalin | Pregabalin | 78 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 77 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 76 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 73 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 46 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 70 | suppressed |
| Amantadine | Amantadine Hcl | 69 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 67 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 66 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 15 |
| Metolazone | Metolazone | 65 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 65 | suppressed |
| Haloperidol | Haloperidol | 62 | suppressed |
| Entresto | Sacubitril/Valsartan | 60 | suppressed |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Trulicity | Dulaglutide | 60 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 13 |
| Nystatin | Nystatin | 59 | 27 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 58 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 58 | suppressed |
| Azathioprine | Azathioprine | 57 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 56 | suppressed |
| Linzess | Linaclotide | 56 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | suppressed |
| Ramipril | Ramipril | 54 | 12 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 53 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 53 | suppressed |
| Mesalamine Er | Mesalamine | 53 | suppressed |
| Sotalol | Sotalol Hcl | 53 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 52 | suppressed |
| Anastrozole | Anastrozole | 51 | suppressed |
| Ethosuximide | Ethosuximide | 50 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 50 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | suppressed |
| Methylprednisolone | Methylprednisolone | 49 | 32 |
| Bupropion Xl | Bupropion Hcl | 48 | 11 |
| Methimazole | Methimazole | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Cephalexin | Cephalexin | 47 | 39 |
| Latanoprost | Latanoprost | 47 | 12 |
| Naproxen | Naproxen | 47 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | suppressed |
| Glipizide | Glipizide | 46 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 46 | suppressed |
| Hydrocortisone | Hydrocortisone | 46 | 14 |
| Amoxicillin | Amoxicillin | 45 | 36 |
| Lansoprazole | Lansoprazole | 45 | suppressed |
| Prednisone | Prednisone | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 42 | suppressed |
| Novolog Flexpen | Insulin Aspart | 41 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 20 |
| Valacyclovir | Valacyclovir Hcl | 38 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Nystop | Nystatin | 33 | suppressed |
| Permethrin | Permethrin | 33 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 30 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Levemir Flexpen | Insulin Detemir | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Jantoven | Warfarin Sodium | 27 | suppressed |
| Restasis | Cyclosporine | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Nyamyc | Nystatin | 26 | 16 |
| Oxycontin | Oxycodone Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Tamoxifen Citrate | Tamoxifen Citrate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ursodiol | Ursodiol | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Rytary | Carbidopa/Levodopa | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 12 |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Thyroid | Thyroid,pork | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Safetyglide Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,724.47 · 137 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AFREZZA, AIRSUPRA, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, COMIRNATY, CONTRAVE, CRYSVITA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, PROQUAD, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, SHINGRIX, SX-ONE MICROKNIFE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error